GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Construction In Progress
Switch to:

Biogen (BUE:BIIB) Construction In Progress

: ARS0 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's quarterly construction in progress increased from Sep. 2022 (ARS0 Mil) to Dec. 2022 (ARS149,007 Mil) but then declined from Dec. 2022 (ARS149,007 Mil) to Mar. 2023 (ARS0 Mil).

Biogen's annual construction in progress declined from Dec. 2020 (ARS158,756 Mil) to Dec. 2021 (ARS77,793 Mil) but then increased from Dec. 2021 (ARS77,793 Mil) to Dec. 2022 (ARS149,007 Mil).


Biogen Construction In Progress Historical Data

The historical data trend for Biogen's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Construction In Progress
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66,304.25 124,592.09 158,756.10 77,792.60 149,007.32

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Construction In Progress Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 149,007.32 -

Biogen Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines

From GuruFocus

Other Sources